Nevro Corp at JPMorgan Healthcare Conference Transcript
Good morning, everyone. I'm Robbie Marcus, a Medical Device Analyst at JPMorgan, and I'm very happy to introduce our next speaker, Keith Grossman, Chairman, CEO and President of Nevro. Keith?
Thank you, Robbie. Good morning, everyone. Welcome to those of you here in the room and those of you joining on the web. My name is Keith Grossman. I will certainly make some forward-looking statements, so I'd refer you to the safe harbor language in our SEC filings.
So Nevro is a leading participant in the spinal cord stimulation for chronic pain market. What does that mean? What we're doing here is we're using predominantly 1 of 2 mechanisms of action to either mask or interrupt the pain signal traveling from the pain site to the brain. This has become a sizable market of about 100,000 patients treated annually. About 80% of that market, by the way, is here in the U.S.
The worldwide market for these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
